Your session is about to expire
← Back to Search
Lonafarnib + Zoledronic Acid + Pravastatin for Progeria
Study Summary
This trial is testing a combination of 3 drugs to see if it can improve the symptoms of Progeria, a rare disease that causes premature death.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Patients must show signs of progeria as determined by the clinical trial team.Your blood, kidney, liver, and vitamin D levels must meet certain requirements.You need to have a genetic test that shows a mutation in the lamin A gene.
- Group 1: Treatment arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the approved treatments that Lonafarnib, Zoledronic Acid, and Pravastatin are used for?
"Lonafarnib, Zoledronic Acid, and Pravastatin are often employed in the treatment of myocardial revascularization. This medical intervention can also be used to improve cardiovascular disease (cvd), hutchinson-gilford progeria syndrome, and low-density lipoproteins."
Do these drugs have Food and Drug Administration sanctioning?
"While there is some safety data for this combination therapy, it received a score of 2 because there are no clinical trials demonstrating its efficacy."
How many people are currently participating in this trial?
"Unfortunately, this study is not presently looking for new patients. The listing was originally posted on August 1st 2009 but was last updated on March 7th 2022. There are other clinical trials underway that may be of interest; including 2 studies recruiting patients with progeria and 55 studies involving Lonafarnib, Zoledronic Acid, and Pravastatin which are actively enrolling patients."
Are there any vacancies in this clinical trial for new patients?
"This is an inactive clinical trial, as indicated by the date of the most recent edit on clinicaltrials.gov. The last update was on March 7th, 2022 and the trial was originally posted August 1st, 2009. There are 57 other trials that patients can participate in at this time."
Share this study with friends
Copy Link
Messenger